UnitedHealth Group: Poised To Challenge The $360 Resistance

Envision ResearchInvesting Group LeaderFollow5ShareSavePlay(9min)Comment(1)SummaryUnitedHealth Group Incorporated is poised for a substantial margin recovery, with FQ1 2026 EPS projected at $6.62 and net margin rebounding to 5.53%.Further margin expansion is likely too, thanks to its strategic repricing, AI-driven efficiency gains, and a 2.48% Medicare Advantage rate increase.UNH trades at a forward P/E of 17.7, about 13% below its five-year average, suggesting sizable undervaluation.Technical signals—including a breakout above the 200-day MA and widening Bollinger Bands—indicate continued upward momentum, targeting a potential $360 UNH share price near term.Looking for a helping hand in the market? Members of Envision Early Retirement get exclusive ideas and guidance to navigate any climate. Learn More » JHVEPhoto/iStock Editorial via Getty Images UNH stock: substantial margin recovery potential I last covered UnitedHealth Group Incorporated (UNH, UNH:CA) on Feb 5, 2026. That article rated the stock as Buy after reviewing its FQ4 2025 earningsThis article was written byEnvision Research20.37K FollowersFollowEnvision Research, aka Lucas Ma, has over 20+ years of investment experience and holds a Masters with in Quantitative Investment and a PhD in Mechanical Engineering with a focus on renewable energy, both from Stanford University. He also has 30+ years of hands-on experience in high-tech R&D and consulting, housing sector, credit sector, and actual portfolio management.He leads the investing group Envision Early Retirement along with Sensor Unlimited where they offer proven solutions to generate both high income and high growth with isolated risks through dynamic asset allocation. Features include: two model portfolios - one for short-term survival/withdrawal and one for aggressive long-term growth, direct access via chat to discuss ideas, monthly updates on all holdings, tax discussions, and ticker critiques by request.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.